GlassScriptPhysician profile
Apurva A Desai
NPI 1861468100
$63,680.68
in general payments reported to CMS, 2019-2025
52 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $4,513 · 2021: $6,735 · 2022: $8,516 · 2023: $1,775 · 2024: $1,596 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,686 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,686.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Education | $196.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56,892.82 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,573.15 | 2019-2025 | |
| Abbvie INC. | $445.15 | 2022-2025 | Venclexta, Lupron Depot |
| Pfizer INC. | $389.82 | 2019-2025 | |
| Astellas Pharma US INC | $383.18 | 2020-2025 | Vyloy, Xtandi, Padcev |
| Gilead Sciences, INC. | $364.12 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $303.17 | 2019-2025 | Imfinzi, Lynparza |
| Celgene Corporation | $246.55 | 2022-2024 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $234.04 | 2020-2025 | Opdivo, Opdualag |
| Boston Scientific Corporation | $210.17 | 2022-2025 | General - Hemostasis, Exalt Model D |
| Tempus Ai, INC | $195.03 | 2024-2025 | Xt Cdx |
| Genentech USA, INC. | $168.99 | 2019-2024 | Tecentriq, Lunsumio, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $166.91 | 2019-2025 | Alunbrig, Ninlaro, Hyqvia |
| Octapharma USA, INC. | $148.05 | 2024 | Panzyga |
| Merck Sharp & Dohme LLC | $122.87 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apurva Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.